Skip to content

Aurinia Pharmaceuticals

US · AUPH #2749 by market cap Listed 1970
14.70 -0.19 -1.28%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15
    Market Newswire · 2026/2/27
  • TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/8/20
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
    TipRanks · 2026/3/31
  • Rating change
    Leerink Partners Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2025/7/2
  • Rating change
    TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
    Market Newswire · 2025/8/1
  • Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21
    Market Newswire · 2026/8/20
  • Rating change
    RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Cuts Target Price to $8
    Market Newswire · 2025/2/28
  • Rating change
    Jefferies Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21
    Market Newswire · 2025/11/7
  • Rating change
    TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $17
    Market Newswire · 2025/11/5
  • Rating change
    Leerink Partners Downgrades Aurinia Pharmaceuticals(AUPH.US) to Hold Rating, Raises Target Price to $16
    Market Newswire · 2025/12/3
  • Rating change
    H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/2/27
  • Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q3 EPS $0.23, Vs. FactSet Est of $0.22
    MT Newswires · 2026/10/30
  • Rating change
    TR | OpenAI - 4o Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $13
    Market Newswire · 2025/8/6
  • Rating change
    RBC Capital Downgrades Aurinia Pharmaceuticals(AUPH.US) to Hold Rating, Raises Target Price to $15
    Market Newswire · 2025/11/5
  • Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $21
    Market Newswire · 2026/11/3
  • Rating change
    Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15
    Market Newswire · 2026/3/31
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Aurinia Pharmaceuticals (AUPH) and RegenXBio (RGNX)
    TipRanks · 2025/5/13
  • Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock
    Market Newswire · 2026/6/3
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
    TipRanks · 2026/3/2
  • Rating change
    H.C. Wainwright Initiates Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Announces Target Price $17
    Market Newswire · 2025/7/30
  • Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q3 Revenue $83.7M, Vs. FactSet Est of $83.6M
    MT Newswires · 2026/10/30
  • Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, Vs. FactSet Est of $0.20
    MT Newswires · 2026/5/7
  • Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M
    MT Newswires · 2026/8/6

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Aurinia Pharmaceuticals discussion 0 comments

Add a comment